Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population
Condition(s):Chronic Myeloid Leukemia (CML)Last Updated:July 7, 2015Completed
Hide Studies Not Open or Pending
Condition(s):Chronic Myeloid Leukemia (CML)Last Updated:July 7, 2015Completed
Condition(s):Colorectal Cancer; Head and Neck CancerLast Updated:February 8, 2019Terminated
Condition(s):Chronic Myeloid LeukemiaLast Updated:February 23, 2017Completed
Condition(s):Chronic Myeloid LeukaemiaLast Updated:May 4, 2017Unknown status
Condition(s):Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)Last Updated:December 8, 2020Completed
Condition(s):Treatment; Stem Cell TransplantationLast Updated:October 12, 2022Completed
Condition(s):Patients Diagnosed as Chronic Meyloid LeukemiaLast Updated:February 22, 2022Unknown status
Condition(s):Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Minimal Residual DiseaseLast Updated:November 28, 2023Recruiting
Condition(s):B-cell Adult Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia; Untreated Adult Acute Lymphoblastic LeukemiaLast Updated:October 30, 2015Withdrawn
Condition(s):Chronic Myeloid LeukemiaLast Updated:January 25, 2023Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.